Appendix adenocarcinoma

Summary

Appendix adenocarcinoma (MONDO:0006087) is a disease and 8 clinical trials. Top therapeutic interventions include bevacizumab, cobimetinib, and famotidine. A subtype of appendix carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	appendix adenocarcinoma
Mondo ID	MONDO:0006087
EFO	EFO:1000088
DOID	DOID:3608
ICD-11	1696330825
NCIT	C7718
SNOMED CT	413445002
UMLS	C0238003
MedGen	65942
GARD	0010564
Anatomy (UBERON)	UBERON:0001154
Is cancer (heuristic)	no

Also known as: adenocarcinoma of appendix · adenocarcinoma of the appendix · APAD · appendiceal adenocarcinoma · appendix adenocarcinoma · vermiform appendix adenocarcinoma

Disease family

This is a subtype of appendix carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › colonic disorder › cecal disorder › cecal neoplasm › appendiceal neoplasm › appendix cancer › appendix carcinoma › appendix adenocarcinoma

Related subtypes (2): goblet cell carcinoma, carcinoma in situ of appendix

Subtypes (1): mucinous adenocarcinoma of the appendix

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	2
PHASE1/PHASE2	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03074513	PHASE2	ACTIVE_NOT_RECRUITING	Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
NCT06207305	PHASE1/PHASE2	RECRUITING	A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
NCT06399757	PHASE1/PHASE2	RECRUITING	A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
NCT03108131	PHASE2	COMPLETED	Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
NCT04665921	PHASE1	TERMINATED	A Study of SGN-STNV in Advanced Solid Tumors
NCT05734430	Not specified	RECRUITING	Genetics of Appendix Cancer Study
NCT05947838	Not specified	RECRUITING	A Prospective Feasibility Study Using ctDNA to Tailor Neoadjuvant Chemotherapy for Patients With Colorectal or Appendiceal Adenocarcinoma
NCT07587268	Not specified	RECRUITING	Molecular Profiling for Risk Stratification in Appendiceal Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1
COBIMETINIB	4	1
FAMOTIDINE	4	1
CHEMBL4538425	0	1